Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma

doi:10.3748/wjg.v22.i38.8447

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 38

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11862)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

765

WORD

279

HTML

5497

Tables (1-2)

630

Sum=7171

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

492

Download

836

Sum=1328

Publishing Process of This Article

Item

Count

Browse

1419

Download

1942

Sum=3361

Oct 14, 2016 (publication date) through Mar 11, 2026

Times Cited of This Article

Times Cited (21)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Review

World J Gastroenterol. Oct 14, 2016; 22(38): 8447-8458
Published online Oct 14, 2016. doi: 10.3748/wjg.v22.i38.8447

Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma

Michele Merli, Giuseppe Carli, Luca Arcaini, Carlo Visco

Michele Merli, Division of Hematology, University Hospital Ospedale di Circolo & Fondazione Macchi, University of Insubria, 36100 Varese, Italy

Giuseppe Carli, Carlo Visco, Department of Cell Therapy and Hematology, San Bortolo Hospital, 36100 Vicenza, Italy

Luca Arcaini, Department of Molecular Medicine, University of Pavia, 27100 Pavia, Italy

Author contributions: Merli M and Visco C made the research; all authors revised the manuscript and gave final inputs before submission.

Conflict-of-interest statement: Authors declare no conflicts of interest.

Correspondence to: Dr. Carlo Visco, Department of Cell Therapy and Hematology, San Bortolo Hospital, Via Rodolfi 37, 36100 Vicenza, Italy. carlovisco@hotmail.com

Telephone: +39-444-753626 Fax: +39-444-753626

Received: June 1, 2016
Peer-review started: June 2, 2016
First decision: July12, 2016
Revised: August 2, 2016
Accepted: August 23, 2016
Article in press: August 23, 2016
Published online: October 14, 2016
Processing time: 132 Days and 20.8 Hours

Core Tip

Core tip: In the last decade many clinical studies demonstrated that front line antiviral therapy (AT) with interferon (IFN) and ribavirin, is able to induce a 70%-75% response rate in patients with hepatitis C virus (HCV)-associated indolent non-Hodgkin lymphoma who do not need immediate conventional treatment. Hematological response was durable, and invariably related to the viral eradication. International guidelines indicate that AT should be the treatment of choice in such patients. Very preliminary data about the use of the new direct-acting antiviral agents (DAAs) suggest a similar activity in inducing lymphoma response. We discuss available literature about IFN-based AT and preliminary experiences with DAAs in the treatment of HCV-associated indolent lymphomas.